(NASDAQ: SNDX) Syndax Pharmaceuticals's forecast annual revenue growth rate of 296.7% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.85%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.43%.
Syndax Pharmaceuticals's revenue in 2024 is $3,500,000.On average, 4 Wall Street analysts forecast SNDX's revenue for 2024 to be $4,547,974,853, with the lowest SNDX revenue forecast at $398,250,955, and the highest SNDX revenue forecast at $9,369,109,016. On average, 5 Wall Street analysts forecast SNDX's revenue for 2025 to be $8,500,615,586, with the lowest SNDX revenue forecast at $6,234,159,187, and the highest SNDX revenue forecast at $11,981,567,206.
In 2026, SNDX is forecast to generate $19,763,799,338 in revenue, with the lowest revenue forecast at $15,350,532,020 and the highest revenue forecast at $28,311,558,307.